Page 1 of 2 ATTY, DOCKET NO. SERIAL NO. Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE 089048-0299 10/645.557 APPLICANT INFORMATION DISCLOSURE CITATION Jhi-Joung WANG FILING DATE **GROUP ART UNIT** 0 122/03 (Use several sheets if necessary) **U.S. PATENT DOCUMENTS** DOCUMENT **EXAMINER** SUB-FILING DATE CLASS REF DATE NAME INITIAL NUMBER CLASS IF APPROPRIATE RD 3,433,791 03/18/1969 Bentley et al. RD 6,004,969 12/21/1999 Ηu 5,750,534 05/12/1998 Yoa-Pu et al. RD RD 6,225,321 B1 05/01/2001 Hu et al. FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT SUB-REF DATE COUNTRY CLASS NUMBER **CLASS** YES NO RD WO 96/28451 PCT 489/02 9/19/96 **C07D** WO 96/16063 5/30/96 PCT **C07D** 489/02 RD OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Hayes et al., "Determination of Receptors that Mediate Opiate Side Effects in the Mouse", Br. J. Pharmac. (1983), 79, 731-736. RD Baxter et al., \*Prevention of Epidural Morphine-Induced Respiratory Depression with Intravenous Nalbuphine Infusion in Post-Thoracotomy RD Patients", Canadian Journal of Anaesthesia (1989) 36:5, pp. 503-509. Bickel et al., "A Clinical Trial of Buprenorphine: Comparison with Methadone in the Detoxification of Heroin Addicts", Clinical Pharmacology RD Therapeutics, January, 1988, Vol. 43, No. 1, pp. 72-78. Fudala et al., "Use of Buprenorphine in the Treatment of Opioid Addiction. II. Physiologic and Behaviooral Effects of Daily and Alternate-day RD Administration and Abrupt Withdrawal', Cl;inical Pharmacology Therapeutics, April 1990, Vol 47, No. 4, pp. 525-534. Imoto et al., 'Transdermal Prodrug Concepts: Permeation of Buprenorphine and its Alkyl Esters through Hairless Mouse Skin and Influence of RΦ Vehicles\*, Biological Pharmaceutical Bulletin, February 1996, Vol. 19, No. 2 pp. 263-267. Stinchcomb et al., "Permeation of Buprenoorphine and iits 3-Alkyl-Ester Prodrugs Through Human Skin", Pharmaceutical Research, Vol. 13, No. RI

Kuhlman et al., "Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenoorphine", Journal of Analytical Toxicology, October,

Stinchcomb et al., "A Solubility and Related Physicochemical Property Comparison of Buprenorphine and Its 3-Alkyl Esters"., Pharmaceutical

RD

RD

10., pp. 1519-1523.

Research.

1996, Vol. 20, No. 6, pp. 337-516.

SEP 2 2 2003

Page 2 of 2 Form PTO-1449 U.S. DEPARTMENT OF COMME Y. DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE (MODIFIED) 089048-0299 10/645,557 APPLICANT INFORMATION DISCLOSURE CITATION Jhi-Joung WANG FILING DATE **GROUP ART UNIT** (Use several sheets if necessary) 08/22/2003 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) RD Buchwald et al. 'Quantitative Structure - Metabolism, etc.' J. Med. Chem. 1999, 42, 5160-5168. Strinchcomb et al. I. "Permeatim of Buprenorphine, etc. " Ca 125: 316126 (1996). RD RD Stinchcomb et al. II "A solubility and related, etc." CA 123: 350075 (1995). Imoto et al. "Transdermal producing concepts: etc" CA 124: 211800 (1996). RD  $\overline{RD}$ Hussain et al. "Improvement of the Oral Bioavailability of Naltrexone in Dogs: A Prodrug Approach" Journal of Pharmaceutical Sciences Vol. 76. No. 5, May 1987, pp. 356-358. Everhart et al. 'Subnanogram-Concentration Measurement of Buprenorphine in Human Plasma by Electron-Capture Capillary Gas RD Chromatography: Application to Pharmacokinetics of Sublingual Buprenorphine Clinical Chemistry 43:12, pp. 2292-2302 (1997). Database Caplus 'Online! Chemical Abstracts Service, Columbus Ohio, US, Database accession no. 1985:608220 XP002238859 RD \*RN 99318-72-6 \* & Yashiki M. et al. \*Dual mass spectrometry of trifluoroacetyl derivatives of opioid bases\* GC-MS News Vol. 13, no. 4, 1985, pp 101-106 (Abstract). 09/15/2006 /Rita Desai/

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ollection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons Substitute for form 1449B/P Complete if Known Application Number 10/645,557 STATEMENT BY APPLICANT 08/22/2003 Filing Date Jhi-Joung WANG First Named Inventor Date Submitted: August 25, 2006 **Group Art Unit** 1614 **Examiner Name** Unassigned (use as many sheets as necessary) 089048-0299 Attorney Docket Number Sheet

_				<b>U.S. PATENT DOCUMENTS</b>			
Examiner Initials*	Cite No.1	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number	Kind Code² (if known)	Document	Cited Document MM-DD-YYYY	Figures Appear	
				FOREIGN PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
		Office <sup>3</sup> Numb	Kind Code <sup>5</sup> (if known)	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	1e
RD	B1	JP 07-196510		NIPPON SEIYAKU KK	8/1/1995		
	ļ				<del></del>	<del></del>	┼

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*  Cite No.!  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or copublished.				
RD	82	Audra L. STINCHCOMB et al., "Permeation of Buprenorphine and Its 3-Alkyl-Ester Prodrugs Through Human Skin", Pharmaceutical Research, 13(10), 1519-1523, 1996.		
			-	
·	ļ		-	

Examiner Signature	/Rita Desai/	Date Considered	09/15/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3), <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.